# Bioprinting of experimental tissue models

Source: https://onco.cc/technologies/bioprinting/  
OnCo record `bioprinting` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bioprinting places cells or materials in a planned arrangement; the constructed tissue still needs structural and functional checks.

## Summary

Bioprinting controls deposition of biological materials to build an experimental construct. The printing plan, measured final geometry, viable cells and biological function are distinct evidence. Kolesky and colleagues printed cell-containing and removable inks, removed the temporary channel material, added endothelial lining and perfused engineered tissues. This tissue-engineering experiment did not demonstrate a complete human organ or cancer-treatment utility. Yi and colleagues reported a particular glioblastoma chip combining patient-derived tumour cells, endothelial cells and brain-derived matrix; its abstract supports that bounded example.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-11-10
- Principle: Deposit defined cells and materials in a planned arrangement, then verify constructed geometry, cell health and the intended function.
- Strengths: Controls a planned starting arrangement for a defined experimental question
- Limitations: The constructed geometry, cell health and intended function must be measured; Fabrication alone does not establish whole-tumour biology, immune recognition or patient benefit

## Notes

- Model card. Input: defined cells and biomaterials, sometimes viable patient-derived material requiring expansion. Document the source of each component; patient-derived tumour cells do not make every material donor-matched. Fabrication and quality checks consume finite material. Output: measured geometry in micrometres or millimetres, viability or attributed counts, and the separately chosen functional endpoint. Retain actual layout, matrix, cell identities, time and controls; a digital plan is not the final measurement. A printing plan specifies positions, materials and fabrication steps. A bioink is a formulation used to build a biological construct, often containing cells in a supportive material. The extracellular matrix is the surrounding molecular scaffold of tissue; a printing material represents selected features rather than its whole composition. A sacrificial ink is temporary material removed to leave a channel. Some designs deposit cells with the material; another route builds a support that is seeded afterwards. Gelation, adding cell populations and making channels are distinct steps. Kolesky's cell-laden and fugitive-ink method is one documented implementation, rather than proof of every possible printing route. Source: https://doi.org/10.1073/pnas.1521342113
- Channel checks. A temporary channel path becomes a hollow channel after removal; endothelial lining, fluid passage and barrier performance require separate tests. Kolesky's primary figures distinguish these steps and compare diffusional permeability of lined and bare channels. Printing describes fabrication; a chip describes an environment, while organoid self-organisation describes another design axis. More complex fabrication does not automatically validate prediction. Living cells can spread, contract and remodel the initial layout. The actual geometry and cell health therefore need observation after printing as well as a design file. In Kolesky's primary PDF, figures 1 and 2 separate fabrication, viability, endothelial lining and measured permeability of lined versus bare channels. Those checks support those engineered tissues, not a complete organ. Perfusion supplies fluid through the constructed system; it is not full human circulation or drug metabolism.
- Fictional reading exercise. Growth changes when both gel composition and neighbour distance change. The comparison does not isolate proximity. Compare layouts with the same material, starting populations and exposure, and verify the final construct. Failure modes include incorrect placement, cell injury, incompatible material and inadequate transport. Acceptance criteria belong to the design; there is no universal clinical printing threshold. Unequal starting composition is another failure mode, alongside placement, compatibility, cell injury and transport. Printing alone does not establish complete tumour biology or immune recognition.

## Sources

- Kolesky et al. 2016 primary fabrication and channel checks: https://doi.org/10.1073/pnas.1521342113
- Yi et al. 2019 primary abstract: https://doi.org/10.1038/s41551-019-0363-x

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Tumour-on-a-chip](https://onco.cc/technologies/tumour-on-chip/)

---
JSON: https://onco.cc/api/v1/entities/bioprinting.json